Timeline
| 2019 | |
|
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1% read more... |
| 2018 | |
|
|
Akorn Receives FDA Approval for Diclofenac Sodium Topical Gel, 1% read more... |
|
|
Akorn Receives FDA Approval for Clobetasol Propionate Lotion, 0.05% read more... |
|
|
Akorn Receives FDA Approval for Bimatoprost Ophthalmic Solution, 0.03% read more... |
| 2017 | |
|
|
Akorn Receives FDA Approval for Mycophenolate Mofetil for Injection, USP read more... |
| 2015 | |
|
|
Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solution read more... |
| 2014 | |
|
|
Akorn Acquires Xopenex® (levalbuterol HCI) Inhalation Solution read more... |
|
|
Akorn Acquires Hi-Tech Pharmacal. read more... |
|
|
Akorn Acquires VersaPharm. read more... |
| 2013-2014 | |
|
|
Akorn Acquires Four Branded Ophthalmic Products: Zioptan®, CosoptPF/Cosopt®, AzaSite®, and Betimol®. |
| 2012 | |
|
|
Generic Vancocin® is approved and launched. |
| 2011 | |
|
|
Advanced Consumer Health is acquired to expand presence in a $1.2 billion over-the-counter eye care market. read more... |
|
|
A Minority Stake in Aciex Therapeutics is acquired providing access to an innovative ophthalmic pipeline. read more... |
|
|
Entered into agreement to acquire assets from Kilitch Drugs of India to expand manufacturing of sterile injectables and global reach. read more... |
|
|
Nembutal®, a Schedule II controlled drug, Diuril® and Cogentin® are acquired from Lundbeck Pharma. |
| 2010 | |
|
|
The Akorn R&D Center in Skokie, IL is opened to provide leading edge capabilities for the development of new and generic pharmaceuticals. |
| 2008 | |
|
|
Corporate Headquarters are moved to Lake Forest, Illinois. |
|
|
Warehousing is relocated to Gurnee, Illinois. |
|
|
Akten® (lidocaine HCI ophthalmic gel) 3.5%, Akorn's first internally developed NDA indicated for topical ocular anesthesia is launched. |
| 2007 | |
|
|
Akorn, Inc. is listed on the NASDAQ exchange. |
| 2004 | |
|
|
Akorn Inc. and Strides Arcolab Ltd. enter into a joint venture as Akorn-Strides, LLC. |
| 2002 | |
|
|
Paremyd® (hydroxyamphetamine hydrobromide and tropicamide, ophthalmic solution), a convenient one-drop dilation agent is launched. |
| 1998 | |
|
|
Advanced Remedies Incorporated is acquired in Somerset, New Jersey, a division of Sidmak laboratories and manufacturer of sterile ophthalic ointments and solutions. |
| 1997 | |
|
|
Akorn Inc. is founded. Corporate headquarters and distribution offices are moved to Buffalo Grove, Illinois. |
|
|
Indocyanine green, now IC-Green®, Akorn's first New Drug Application (NDA) ophthalmic drug for retina diagnostic imaging, is acquired from Becton Dickinson (BD). |
| 1996 | |
|
|
Taylor Pharmacal Company begins operating under the name of Akorn Manufacturing. |
|
|
Pasadena Research Laboratories in Pasadena, California is acquired along with its injectable line of products. |
| 1994 | |
|
|
The Grand facility in Decatur is expanded to add ophthalmic filling operations. |
| 1992 | |
|
|
The Taylor family sells Taylor Pharmacal Company to Akorn Inc., a Louisiana based ophthalmic sales and distribution company, that owns ophthalmic products under the Akorn Ophthalmics label. |
| 1977 | |
|
|
The Wyckles facility in Decatur, Illinois is constructed to provide packaging and warehouse operation and to allow expansion of the filling and laboratory testing areas at the Grand facility. |
| 1971 | |
|
|
Akorn Ophthalmics is founded in Abita Springs, Louisiana |
| 1953 | |
|
|
The Grand facility in Decatur, Illinois is constructed to provide a filling and packaging location for the manufacture of pharmaceutical products. |
| 1948 | |
|
|
Taylor Pharmacal is founded by Guy Taylor and his two sons in Decatur Illinois. |